Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
Minkyu Jung, Jeeyun Lee, Tae Min Kim, Dae Ho Lee, Jin Hyung Kang, Sung Young Oh, Soo Jung Lee, Sang Joon Shin
Cancer Res Treat. 2017;49(1):44-53.   Published online 2016 Apr 27     DOI: https://doi.org/10.4143/crt.2016.024
Citations to this article as recorded by Crossref logo
MelRisk: Using neutrophil-to-lymphocyte ratio to improve risk prediction models for metastatic cutaneous melanoma in the sentinel lymph node
Ryckie G. Wade, Samuel Bailey, Alyss V. Robinson, Michelle C.I. Lo, Howard Peach, Marc D.S. Moncrieff, James Martin
Journal of Plastic, Reconstructive & Aesthetic Surgery.2022; 75(5): 1653.     CrossRef
The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy
Yayun Li, Yu Meng, Huiyan Sun, Lin Ye, Furong Zeng, Xiang Chen, Guangtong Deng
Journal of Immunotherapy.2022; 45(1): 43.     CrossRef
The pharmacotherapeutic management of nail unit and acral melanomas
Julianne M. Falotico, Shari R. Lipner
Expert Opinion on Pharmacotherapy.2022; 23(11): 1273.     CrossRef
Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Yongchao Zhang, Bozhi Liu, Sergei Kotenko, Wei Li
Medicine.2022; 101(32): e29536.     CrossRef
Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada
Wei Fang Dai, Jaclyn Beca, Ruth Croxford, Wanrudee Isaranuwatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna, Kelvin K. W. Chan
International Journal of Cancer.2021; 148(8): 1910.     CrossRef
Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis
Náthali Felícia Mineiro dos Santos Garrett, Ana Cristina Carvalho da Costa, Elaine Barros Ferreira, Giovanni Damiani, Paula Elaine Diniz dos Reis, Christiane Inocêncio Vasques, Gayle E. Woloschak
PLOS ONE.2021; 16(8): e0255716.     CrossRef
Novel Prognostic Immunohistochemical Markers in Uveal Melanoma-Literature Review
Malgorzata Gajdzis, Radoslaw Kaczmarek, Pawel Gajdzis
Cancers.2021; 13(16): 4031.     CrossRef
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Anja Wessely, Theresa Steeb, Michael Erdmann, Lucie Heinzerling, Julio Vera, Max Schlaak, Carola Berking, Markus Vincent Heppt
International Journal of Molecular Sciences.2020; 21(3): 879.     CrossRef
Neutrophil diversity and plasticity in tumour progression and therapy
Sebastien Jaillon, Andrea Ponzetta, Diletta Di Mitri, Angela Santoni, Raffaella Bonecchi, Alberto Mantovani
Nature Reviews Cancer.2020; 20(9): 485.     CrossRef
Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis
Kelcie Witges, Leigh Anne Shafer, Ryan Zarychanski, Ahmed M. Abou-Setta, Rasheda Rabbani, Orvie Dingwall, Charles N. Bernstein
Drug Safety.2020; 43(12): 1255.     CrossRef
Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis
Fausto Petrelli, Raffaele Ardito, Barbara Merelli, Veronica Lonati, Mary Cabiddu, Silvia Seghezzi, Sandro Barni, Antonio Ghidini
Melanoma Research.2019; 29(1): 1.     CrossRef
Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non–Small-Cell Lung Cancer
Wungki Park, Gilberto Lopes
Clinical Lung Cancer.2019; 20(3): 143.     CrossRef
Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors
Xianhe Xie, Junjin Liu, Haitao Yang, Huijuan Chen, Sijing Zhou, Heng Lin, Ziyuan Liao, Yin Ding, Liting Ling, Xuewen Wang
Cancer Investigation.2019; 37(6): 265.     CrossRef
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Ernesto Rossi, Giovanni Schinzari, Ilaria Grazia Zizzari, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Vincenzo Fiorentino, Gianluigi Petrone, Alessandra Cassano, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Marianna Nuti, Gia
Cancers.2019; 11(8): 1055.     CrossRef
Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes
Lucy T. Xu, Pauline F. Funchain, James F. Bena, Manshi Li, Ahmad Tarhini, Eren Berber, Arun D. Singh
Ocular Oncology and Pathology.2019; 5(5): 323.     CrossRef
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
Tao Jiang, Meng Qiao, Chao Zhao, Xuefei Li, Guanghui Gao, Chunxia Su, Shengxiang Ren, Caicun Zhou
Cancer Immunology, Immunotherapy.2018; 67(5): 713.     CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio in melanoma
Yingguo Ding, Shan Zhang, Jianjun Qiao
Medicine.2018; 97(30): e11446.     CrossRef
Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study
Tony Ibrahim, Christine Mateus, Maria Baz, Caroline Robert
Cancer Immunology, Immunotherapy.2018; 67(10): 1571.     CrossRef
Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
Qiaoyun Tan, Shuxia Liu, Caixia Liang, Xiaohong Han, Yuankai Shi
Thoracic Cancer.2018; 9(10): 1220.     CrossRef
Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma
Francesco S. Mennini, Chiara Bini, Andrea Marcellusi, Michele Del Vecchio
Clinical Drug Investigation.2018; 38(10): 967.     CrossRef
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review
Markus V. Heppt, Theresa Steeb, Justin Gabriel Schlager, Stefanie Rosumeck, Corinna Dressler, Thomas Ruzicka, Alexander Nast, Carola Berking
Cancer Treatment Reviews.2017; 60: 44.     CrossRef
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
Charissa A. C. Jessurun, Julien A. M. Vos, Jacqueline Limpens, Rosalie M. Luiten
Frontiers in Oncology.2017;[Epub]     CrossRef